Antitumor Activity of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor in Cholangiocarcinoma Models With FGFR2-fusion
Sign Up to like & getrecommendations! Published in 2024 at "AntiCancer Research"
DOI: 10.21873/anticanres.17046
Abstract: Background/Aim: Cholangiocarcinoma (CCA) is an aggressive tumor with limited treatment options especially in 2nd line or later treatments. Targeting fibroblast growth factor receptor (FGFR) 2 has recently emerged as a promising treatment option for patients… read more here.
Keywords: orally available; fgfr2 fusion; available fgfr1; fgfr1 inhibitor ... See more keywords